Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Neuroblastoma

 

Melphalan and Buthionine Sulfoximine Followed by Bone Marrow Transplant for Children With Resistant or Recurrent Neuroblastoma (NANT 9902)
Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) with Autologous Stem Cell Support for Resistant/Recurrent High-Risk Neuroblastoma (IND #69,112)

Investigator: Julie Park, MD;   Conditions: Neuroblastoma;    Status: Recruiting;   Study ID: NCT00005835

Fenretinide LXS for Recurrent, Refractory, or Persistent Neuroblastoma (NANT 2004-04)
Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma (IND # 68254)

Investigator: Julie Park, MD;   Conditions: Neuroblastoma;    Status: Recruiting;   Study ID: NCT00295919

Intravenous Fenretinide for Young Patients With Recurrent or Resistant Neuroblastoma (NANT 2004-03)
A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children with Recurrent or Resistant Neuroblastoma (IND #70,058)

Investigator: Julie Park, MD;   Conditions: Neuroblastoma;    Status: Closed;   Study ID: NCT00646230

Combination Chemotherapy and Surgery w/wo Isotretinoin in Treating Young Patients With Neuroblastoma (COG ANBL0531)
Response-and Biology-based Therapy for Intermediate Risk Neuroblastoma

Investigator: Julie Park, MD;   Conditions: Neuroblastoma;    Status: Closed;   Study ID: NCT00499616

Cyclophosphamide and Prednisone w/wo Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma (COG ANBL00P3)
A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone

Investigator: Julie Park, MD;   Conditions: Neuroblastoma;    Status: Recruiting;   Study ID: NCT00033293

Isotretinoin w/wo Monoclonal Antibody, Interleukin-2, and Sargramostim post STM (COG ANBL0032)
Phase III, Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High-Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

Investigator: Julie Park, MD;   Conditions: Neuroblastoma;    Status: Recruiting;   Study ID: NCT00026312